HB3731, the Small Biotech Innovation Act, would amend the Medicare drug price negotiation provisions of the Social Security Act to create a new exception for certain small biotech manufacturers beginning with initial price applicability year 2029. Under the bill, a qualifying single-source drug made by a “research and development-intensive small biotech manufacturer” would be excluded from the negotiation-eligible drug list, provided the manufacturer meets specified size, ownership, and R&D-spending thresholds.
The bill defines a small biotech manufacturer as one with five or fewer qualifying single-source drugs that is not controlled by, owned by, or subject to the direction of a foreign government or covered nation. To qualify for the exception, the manufacturer must spend a minimum percentage of its average net revenue from the prior three years on research and development, with the required percentage rising from 30% to 70% depending on how many qualifying drugs the company has. The bill also requires annual applications to the Secretary of Health and Human Services, including financial information and certifications, and directs the Secretary to create an appeal process for adverse determinations.
Impact
If enacted, the bill would narrow the scope of drugs subject to Medicare price negotiation by carving out certain small, R&D-heavy biotech firms from the negotiation program. It would amend section 1192(d)(2) of the Social Security Act and affect how the Centers for Medicare & Medicaid Services and the Secretary of Health and Human Services identify negotiation-eligible drugs starting in 2029. The measure would primarily affect small biotech manufacturers, their qualifying single-source drugs, and the administrative process for determining eligibility and resolving disputes.
Sentiment
The available legislative record shows introduction and referral only, with no committee transcript or recorded votes provided. Based on the bill’s structure and title, the measure appears intended to support biotech innovation and protect smaller research-intensive companies from Medicare price negotiation requirements. Because there is no recorded debate or vote history in the materials provided, there is no direct evidence of support or opposition in committee or on the floor.
Contention
The main policy tension is between protecting innovation incentives for small biotech firms and preserving the reach of Medicare’s drug price negotiation program. Supporters are likely to argue that high R&D spending and limited product portfolios make these companies more vulnerable to negotiation and that an exception would encourage continued investment in drug development. Opponents may argue that the exemption weakens Medicare’s bargaining power, creates a carve-out that could be exploited, and reduces expected prescription drug savings for beneficiaries and the federal government. The foreign ownership and acquisition provisions suggest additional concern about limiting the exception to domestically controlled firms and preventing post-acquisition gaming of the rule.
Creates "Manufacturing Reboot Program" in EDA to provide financial assistance to certain manufacturing businesses; makes $10 million appropriation to EDA.
Creates "Manufacturing Reboot Program" in EDA to provide financial assistance to certain manufacturing businesses; makes $10 million appropriation to EDA.